Opiant Pharmaceuticals, (NASDAQ: OPNT), which develops pharmacological solutions for addictions, disorders and substance abuse, announced that it has entered into an agreement with Sanofi (NYSE: SNY) to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose (ACO). Drinabant, a selective CB1...
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its lead drug candidate for the treatment of agitation in patients suffering from Schizophrenia. The drug candidate was granted a fast track designation...
There is never a dull day in the Cannabis Industry! Each day brings news of consolidations, expansions and diversification of established as well new entrants in the cannabis space, eager to make gains, in the possible event of legalization of Cannabis in the U.S. This year...
The shares of Curaleaf (OTCQX: CURLF) surged by almost 15% since the news of its acquisition of Cura Partners, the owner of Select brand, in an all-stock deal valued at C$1.27 billion or US$948.8 million became public. The deal will offer both the companies the ability to diversify and leverage...
The Canadian cannabis behemoth Canopy Growth Inc (NYSE:CGC), a global leader in diversified cannabis and hemp related products, entered into a definitive agreement with Acreage Holdings, Inc (OTCQX: ACRGF) that bestows it with the right to acquire 100 percent of the company’s shares at such time as cannabis production and...
Parkinson’s is the second most common age-related neurodegenerative disorder, characterized by muscle rigidity, bradykinesia, cognitive impairment, etc. An estimated one million people in the USA are currently battling this disease, with over 60,000 new diagnoses each year. The cost of healthcare is a staggering $25...
Multiple Sclerosis (MS) is one of the diseases that will be covered under the National Neurological Conditions Surveillance System (NNCSS), a system that is being built by the Centers for Disease Control and Prevention (CDC) as part of the 21st Century Cures Act 2016, which has finally received funding in 2019...
The Global Market for Insomnia is estimated to reach $5,488 million by 2023 from $4,093 million in 2016 at a CAGR of 4.2% according to a report titled “Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription...
